reports
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 R...
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia - Data expected in Q2 2026 - DUBLIN, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced the completion of patient enrollment in REVITALYZ, a Phase 3 trial evaluating LUMRYZTM (sodium oxybate) extended-release oral suspension as a potential treatment for idiopathic hypersomnia (IH). REVITALYZ is a double-blind, placebo-controlled, randomized withdrawal, multicen...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Full House Resorts, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 8 December 2025 in which we reassessed the appropriateness of the ratings in the c...
Announcement relating to despatch of Rule 15 proposal
Announcement relating to despatch of Rule 15 proposal NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 15(C) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- As previously announced, the board of directors of Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public limited company incorporated in Ireland (the “Company” or ...
Announcement relating to despatch of Definitive Proxy Statement and de...
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 17(B) (AS AMENDED BY SECTION 3 OF APPENDIX 4) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- As previously announced, the board of directors...
Announcement relating to convening of Scheme Meeting and Extraordinary...
Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 17(A) (AS AMENDED BY SECTION 3 OF APPENDIX 4) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) FOR IMMEDIATE RELEASE DUBLIN, Dec. 01, 2025 (GLOBE NEWSWIRE) -- As previously announced, the board of directors of Avadel Pharmac...
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare C...
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference Fireside chat scheduled for Tuesday, December 2, 2025 at 12:30 PM ET NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025. The fireside chat is scheduled to take place on Tuesday, December 2, 2025, at 12:30 PM ET. A live webcast of the fireside chat will be available on the Eve...
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Confe...
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Wednesday, December 3, 2025, at 10:10 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the “Investors” section of the Company’s website at and will be available for replay on that site following the ...
RGC Resources, Inc. Raises Annual Dividend to $0.87 Per Share
RGC Resources, Inc. Raises Annual Dividend to $0.87 Per Share ROANOKE, Va., Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO), at its meeting on November 24, 2025, declared a quarterly dividend of $0.2175 per share on the Company’s common stock. The indicated annual dividend is $0.87 per share, a $0.04, or 4.8% per share increase over the prior annual level. The Company has now increased the annual dividend 22 consecutive years. Paul Nester, CEO of RGC Resources, Inc., stated, “The Board’s decision to increase the annual dividend rate reflects ...
RGC Resources, Inc. Schedules Fourth Quarter 2025 Earnings Call
RGC Resources, Inc. Schedules Fourth Quarter 2025 Earnings Call ROANOKE, Va., Nov. 20, 2025 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) will host its quarterly conference call and webcast to review the results of its fiscal fourth quarter 2025 on Thursday, December 4, 2025 at 9:00 a.m. eastern time. Related presentation materials will be available before the call on the Company website on the Investor & Financial Information page at .Interested parties may access the conference call by dialing toll-free 1-877-304-9269 and entering conference identification number 917621. An arc...
RGC Resources, Inc. Reports 2025 Earnings
RGC Resources, Inc. Reports 2025 Earnings ROANOKE, Va., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $13.3 million, or $1.29 per share, for the fiscal year ended September 30, 2025, compared to $11.8 million, or $1.16 per share, for the fiscal year ended September 30, 2024. The strong increase reflected record levels of gas deliveries aided by higher operating margins, partially offset by inflationary cost increases and lower equity earnings from the Company’s investment in the Mountain Valley Pipeline (MVP). MVP’s equity ...
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of Ameri...
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 27 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year. The Company’s growth between fiscal years 2021 to 2024 was fueled by BRIUMVI® revenues, which was approved in the United States by the Food and Drug Administration (FDA) t...
Interparfums, Inc. Announces Initial 2026 Guidance
Interparfums, Inc. Announces Initial 2026 Guidance NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced initial guidance for its fiscal year ending December 31, 2026. Guidance2026E2025E% ChangeNet Sales$1.48B$1.47B+1%Diluted EPS$4.85$5.12(5%) Management CommentaryJean Madar, Chairman & Chief Executive Officer of Interparfums noted, “In 2026, we will focus on consolidation and lay the foundations for long term, profitable growth. While current market dynamics largely influence a conservative outlook for 2026, w...
Avadel Board of Directors Declares Lundbeck Proposal a “Company Superi...
Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal” THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) AND IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE...
Avadel Receives Unsolicited Proposal from Lundbeck
Avadel Receives Unsolicited Proposal from Lundbeck THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) AND IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE ...
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammati...
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit Fireside chat scheduled for Wednesday November 12, 2025 at 10:00 AM ET NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12 – 13, 2025. The fireside chat is scheduled to take place on Wednesday, November 12, 2025, at 10:00 AM ET. A live webcast of the fireside chat will be ava...
Full House Resorts Announces Strong Third Quarter Results
Full House Resorts Announces Strong Third Quarter Results - American Place Casino Continued Its Strong Growth, With Revenues Increasing 14.0% to a New Property Record in the Third Quarter of 2025 - Consolidated Operating Income Rose 40.3% to $3.4 Million in the Third Quarter of 2025; Net Loss Improved to $(7.7) Million from $(8.5) Million - Adjusted EBITDA Increased 26.1% to $14.8 Million in the Third Quarter of 2025, Reflecting Strong Results at American Place and a $2.1 Million Contribution from Chamonix/Bronco Billy’s LAS VEGAS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Full House Resorts,...
Interparfums, Inc. Reports 2025 Third Quarter Results
Interparfums, Inc. Reports 2025 Third Quarter Results FY2025 Guidance Refined to Reflect Market Dynamics NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) today reported results for the third quarter and nine months ended September 30, 2025. Financial Highlights:($ in millions, except per share amounts)Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20252024% Change20252024% ChangeNet Sales$430$425+1%$1,102$1,091+1%Gross Margin63.5%63.9%(40) bps64.4%63.6%+80 bpsOperating Income$109$106+2%$243$239+2%Operating Margin25.3%25.0%+30 bps22.0%21.9%+1...
FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc
FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ap9 FORM 8.1(a) & (b)(Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1. KEY INFORMATION (a) Full name of discloser:Avadel Pharmaceuticals plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and benefici...
Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results an...
Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update – Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September 30, 2025, a 48% increase compared to September 30, 2024 – – Announced global settlement of all litigation with Jazz Pharmaceuticals, Inc. (“Jazz”) – – Acquisition by Alkermes plc (“Alkermes”) expected to close in first quarter 2026 – DUBLIN, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharma...
Bioventus Reports Third Quarter Financial Results
Bioventus Reports Third Quarter Financial Results Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8%Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per diluted shareNon-GAAP earnings* of $0.15 per diluted share increased 200%Cash from operations of $30.1 million increased 192%Company reaffirms revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.